EP3585420A4 - Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant - Google Patents

Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant Download PDF

Info

Publication number: EP3585420A4
Authority: EP; European Patent Office
Prior art keywords: peptides; methods; same; related disorders; dystrophy
Prior art date: 2017-02-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP18756867.0A

Other languages

German (de)

English (en)

Other versions

EP3585420A2 (fr

Inventor

Eytan R. Barnea

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

BioIncept LLC

Original Assignee

BioIncept LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-02-22

Filing date

2018-02-22

Publication date

2021-04-07

2018-02-22 Application filed by BioIncept LLC filed Critical BioIncept LLC

2018-02-22 Priority to EP22150813.8A priority Critical patent/EP4066850A3/fr

2020-01-01 Publication of EP3585420A2 publication Critical patent/EP3585420A2/fr

2021-04-07 Publication of EP3585420A4 publication Critical patent/EP3585420A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP18756867.0A 2017-02-22 2018-02-22 Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant Withdrawn EP3585420A4 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
EP22150813.8A EP4066850A3 (fr)	2017-02-22	2018-02-22	Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762462292P	2017-02-22	2017-02-22
PCT/US2018/019279 WO2018156801A2 (fr)	2017-02-22	2018-02-22	Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
EP22150813.8A Division EP4066850A3 (fr)	2017-02-22	2018-02-22	Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant

Publications (2)

Publication Number	Publication Date
EP3585420A2 EP3585420A2 (fr)	2020-01-01
EP3585420A4 true EP3585420A4 (fr)	2021-04-07

Family

ID=63253026

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP22150813.8A Withdrawn EP4066850A3 (fr)	2017-02-22	2018-02-22	Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant
EP18756867.0A Withdrawn EP3585420A4 (fr)	2017-02-22	2018-02-22	Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP22150813.8A Withdrawn EP4066850A3 (fr)	2017-02-22	2018-02-22	Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant

Country Status (6)

Country	Link
EP (2)	EP4066850A3 (fr)
CN (1)	CN110869044A (fr)
AU (1)	AU2018225163A1 (fr)
CA (1)	CA3054366A1 (fr)
IL (1)	IL268844A (fr)
WO (1)	WO2018156801A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US12254090B2 (en)	2021-08-26	2025-03-18	International Business Machines Corporation	Filesystem object protection from ransomware attacks

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20160263186A1 (en) *	2013-10-22	2016-09-15	Bioincept, Llc	Pif-transfected cells and methods of use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1404877B1 (fr)	2001-07-02	2010-01-06	Bioincept, LLC.	Dosages pour le facteur preimplantatoire et peptides du facteur preimplantatoire
US8222211B2 (en)	2001-07-02	2012-07-17	Bioincept, Llc	Methods of administering PIF agonist peptides and uses thereof
US7723290B2 (en)	2004-10-22	2010-05-25	Bioincept, Llc	Compositions and methods for modulating the immune system
US7723289B2 (en)	2003-10-22	2010-05-25	Bioincept, Llc	PIF tetrapeptides
CA3005835C (fr)	2004-12-22	2023-01-31	Ambrx, Inc.	Compositions contenant des acides amines non naturels et des polypeptides, procedes impliquant ces acides amines non naturels et polypeptides, et utilisations desdits acides amines non naturels et polypeptides
EP1793398A1 (fr)	2005-12-05	2007-06-06	Sokymat Automotive GmbH	Dispositif de fixation pour und composant électronique et unité de fabrication avec table tournante
CA2645844C (fr) *	2006-03-13	2016-04-26	Liat Mintz	Utilisation d'une variante de la ghreline pour traiter la cachexie, et/ou l'anorexie-cachexie, et/ou la malnutrition, et/ou la lipodystrophie, et/ou la perte de muscles, et/ou stimuler l'appetit;
US8916532B2 (en) *	2008-04-28	2014-12-23	The Trustees Of The University Of Pennsylvania	Methods for enhancing utrophin production via inhibition of microRNA
WO2010115050A2 (fr) *	2009-04-01	2010-10-07	The Regents Of The University Of California	Microarn spécifiques de cellules souches embryonnaires, qui favorisent la pluripotence induite
WO2012166559A1 (fr)	2011-05-27	2012-12-06	Ambrx, Inc.	Compositions contenant des dérivés de dolastatine liés à des acides aminés non naturel
EP2764140B1 (fr)	2011-10-07	2017-08-30	Bicycle Therapeutics Limited	Modulation d'une spécificité de polypeptide structuré
US8987414B2 (en)	2012-02-15	2015-03-24	Aileron Therapeutics, Inc.	Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CA2873511A1 (fr)	2012-05-17	2013-11-21	Ra Pharmaceuticals, Inc.	Inhibiteurs de peptides et de peptidomimetiques
CA2887285A1 (fr)	2012-11-01	2014-05-08	Aileron Therapeutics, Inc.	Acides amines disubstitues et procedes de preparation et d'utilisation de ceux-ci
WO2014138429A2 (fr)	2013-03-06	2014-09-12	Aileron Therapeutics, Inc.	Macrocycles peptidomimétiques et leur utilisation dans la régulation de hif1alpha
US20160250188A1 (en) *	2013-10-25	2016-09-01	Ernest D. Bush	Methods for treatment of muscular dystrophies
WO2016044493A1 (fr) *	2014-09-16	2016-03-24	Bioincept, Llc	Compositions et méthodes permettant le traitement d'un syndrome d'irradiation aiguë

2018
- 2018-02-22 CA CA3054366A patent/CA3054366A1/fr active Pending
- 2018-02-22 AU AU2018225163A patent/AU2018225163A1/en not_active Abandoned
- 2018-02-22 EP EP22150813.8A patent/EP4066850A3/fr not_active Withdrawn
- 2018-02-22 CN CN201880026431.1A patent/CN110869044A/zh active Pending
- 2018-02-22 WO PCT/US2018/019279 patent/WO2018156801A2/fr not_active Ceased
- 2018-02-22 EP EP18756867.0A patent/EP3585420A4/fr not_active Withdrawn
2019
- 2019-08-22 IL IL26884419A patent/IL268844A/en unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20160263186A1 (en) *	2013-10-22	2016-09-15	Bioincept, Llc	Pif-transfected cells and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PATRIZIA PESSINA ET AL: "Novel and optimized strategies for inducing fibrosis in vivo: focus on Duchenne Muscular Dystrophy", SKELETAL MUSCLE, BIOMED CENTRAL LTD, LONDON, UK, vol. 4, no. 1, 25 August 2014 (2014-08-25), pages 7, XP021193544, ISSN: 2044-5040, DOI: 10.1186/2044-5040-4-7 *
UTPAL BASU ET AL: "Translational Regulation of Utrophin by miRNAs", PLOS ONE, vol. 6, no. 12, 27 December 2011 (2011-12-27), pages e29376, XP055751401, DOI: 10.1371/journal.pone.0029376 *

Also Published As

Publication number	Publication date
WO2018156801A2 (fr)	2018-08-30
WO2018156801A3 (fr)	2019-02-21
EP4066850A2 (fr)	2022-10-05
CN110869044A (zh)	2020-03-06
CA3054366A1 (fr)	2018-08-30
EP4066850A3 (fr)	2022-11-23
EP3585420A2 (fr)	2020-01-01
IL268844A (en)	2019-10-31
AU2018225163A1 (en)	2019-09-19

Publication	Publication Date	Title
EP3720502A4 (fr)	2022-01-19	Produits cytobiologiques et leurs utilisations thérapeutiques
EP3474785A4 (fr)	2020-03-04	Implant vertébral et ses procédés d'utilisation
EP3684821A4 (fr)	2021-06-16	Anticorps anti-hla-a2 et leurs procédés d'utilisation
EP3429584A4 (fr)	2019-11-13	Compositions et méthodes de traitement de la presbytie
ZA201905851B (en)	2021-04-28	Peptides and methods for the treatment of diabetes
EP3651747A4 (fr)	2020-07-22	Compositions et méthodes de traitement de troubles oculaires
EP3348273B8 (fr)	2019-09-18	Compositions à base de protéines et de xyloglucane pour le traitement de troubles intestinaux
EP3245241A4 (fr)	2018-04-18	Polyélectrolytes conjugués et leurs procédés d'utilisation
EP3755148A4 (fr)	2021-12-15	Nanosuspensions de salsalate et leurs procédés d'utilisation
EP3377085A4 (fr)	2019-07-17	Peptides et méthodes de traitement de l'endométriose utilisant lesdits peptides
EP3258930A4 (fr)	2018-10-17	Oxabicycloheptanes et oxabicycloheptènes permettant de traiter des troubles dépressifs et de stress
EP3341739A4 (fr)	2019-07-10	Peptides mutants et procédés de traitement de sujets les employant
EP3334730A4 (fr)	2018-12-26	Pyrrolomycines et leurs procédés d'utilisation
EP3691748A4 (fr)	2021-07-07	Combinaisons d'acétaminophène-prégabaline et procédés de traitement de la douleur
IL268844A (en)	2019-10-31	Peptides and methods of treating dystrophy-related diseases by them
EP3554494A4 (fr)	2021-02-17	Compositions et méthodes pour le traitement d'une inflammation
IL269817A (en)	2019-11-28	Medicinal cells in macrocapsules and methods of using them
EP3732204A4 (fr)	2022-01-19	Anticorps anti-rénalase pour le traitement et la prévention de maladies et de troubles
HK40021181A (en)	2020-10-30	Peptides and methods of treating dystrophy-related disorders using the same
EP3265482A4 (fr)	2018-11-21	Protéine de ciblage d'intégrine et procédés pour l'utiliser
HK40109502A (en)	2024-12-06	Anti-renalase antibodies for the treatment and prevention of diseases and disorders
HK40048227A (en)	2021-11-26	Therapeutic uses and methods
HK40034329A (en)	2021-04-23	Compositions and methods for the treatment of allergy
HK40017878A (en)	2020-09-25	Multibiotic agents and methods of using the same
AU2018901531A0 (en)	2018-05-17	Therapeutic uses and methods

Legal Events

Date	Code	Title	Description
2018-09-01	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2019-12-05	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2019-12-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2020-01-01	17P	Request for examination filed	Effective date: 20190917
2020-01-01	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2020-01-01	AX	Request for extension of the european patent	Extension state: BA ME
2020-05-27	DAV	Request for validation of the european patent (deleted)
2020-05-27	DAX	Request for extension of the european patent (deleted)
2020-10-30	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 40021181 Country of ref document: HK
2021-01-06	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 38/10 20060101ALI20201127BHEP Ipc: A61K 45/06 20060101ALI20201127BHEP Ipc: A61K 38/04 20060101ALI20201127BHEP Ipc: A61K 38/17 20060101ALI20201127BHEP Ipc: A61K 38/08 20190101ALI20201127BHEP Ipc: A61P 21/00 20060101ALI20201127BHEP Ipc: A61K 38/19 20060101AFI20201127BHEP
2021-04-07	A4	Supplementary search report drawn up and despatched	Effective date: 20210309
2021-04-07	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 38/19 20060101AFI20210302BHEP Ipc: A61K 38/10 20060101ALI20210302BHEP Ipc: A61K 45/06 20060101ALI20210302BHEP Ipc: A61K 38/17 20060101ALI20210302BHEP Ipc: A61K 38/08 20190101ALI20210302BHEP Ipc: A61K 38/04 20060101ALI20210302BHEP Ipc: A61P 21/00 20060101ALI20210302BHEP
2022-12-23	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2023-01-25	18D	Application deemed to be withdrawn	Effective date: 20220901